Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alirocumab for arterial wall inflammation in statin-intolerant high cardiovascular risk patients
2016-004794-41Phase 4Active
- Sponsor
- Amsterdam UMC
- Start
- Feb 2017
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of alirocumab in cardiac morbidity, sponsored by Amsterdam UMC. Primary endpoint: Change in arterial wall 18F-FDG target-to-background ratio. Started Feb 2017; status: active.
02
Drugs
alirocumab
03
Conditions
cardiac morbidity
Beyond the preview
Go deeper on 2016-004794-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004794-41.